SCHEMBL8288207

SCHEMBL8288207

CC(C)(C)OC(=O)N1CCCC1CNc1nc(-c2ccc(S(C)(=O)=O)cc2)no1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 13/20 0.44
HDAC4 P56524 3/20 0.42
HDAC6 Q9UBN7 2/20 0.42
OPRD1 P41143 1/20 0.42
PRMT5 O14744 1/20 0.42
APP P05067 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
DRD2 P14416 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
SLC6A2 P23975 1/20 0.41
HRH2 P25021 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR7 P34969 1/20 0.41
DRD3 P35462 1/20 0.41
OPRK1 P41145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4953572 1.00 GPR119 (0.44) GPR119HDAC4HDAC6OPRD1PRMT5
SCHEMBL8288204 0.88 PRMT5 (0.48) GPR119HDAC4HDAC6OPRD1PRMT5
SCHEMBL4414041 0.84 GPR119 (0.55) GPR119HDAC4
SCHEMBL14282800 0.82 USP30 (0.52)
SCHEMBL8288202 0.82 GRM5 (0.51)
SCHEMBL4954742 0.82 USP30 (0.52)
SCHEMBL4958769 0.82 GRM5 (0.51)
SCHEMBL4954866 0.80 GRM5 (0.46) OPRD1PRMT5DPP4DPP7
SCHEMBL8290315 0.80 GRM5 (0.46) OPRD1PRMT5DPP4DPP7
SCHEMBL14282808 0.80 DPP4 (0.51) GPR119DPP4DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080027035-A1 Dpp-Iv Inhibitors GRAFFINITY PHARMACEUTICALS AG (DE) 2008-01-31 US disclosed
US-20080027035-A1 Dpp-Iv Inhibitors GRAFFINITY PHARMACEUTICALS AG (DE) 2008-01-31 US disclosed
EP-1613304-B1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS CH (CH) 2007-09-12 EP disclosed
WO-2005056003-A1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027035-A1 Dpp-Iv Inhibitors DPP4, DPP7, DPP3 GPR119 71/4885HDAC4 384/4885HDAC6 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.